Jorg Schelfhout is the founder and chief scientific officer of Allegro Biotech, a Belgium-based company dedicated to developing next-generation injectable hydrogel platforms for orthopedic and regenerative medicine. His work at Allegro focuses on translating lab-scale formulations into scalable, regulatory-ready products designed for intra-articular use. Dr. Schelfhout holds a Ph.D. in biomedical engineering from Ghent University, where his research focused on the development of injectable hydrogels for soft tissue engineering.